Skip to content

Total Assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$86.48B-6.4%
Eli Lilly logo
Eli LillyLLY
$116.58B+30.4%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$24.5B-7.3%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.3B-1.2%
Prime Medicine logo
Prime MedicinePRME
$294.73M-10.2%
Wave Life Sciences logo
Wave Life SciencesWVE
$583.54M+102%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$587.04M+192%
Enterprise value$534.72M+232%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0.0×
Current ratio56×

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's total assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monopar Therapeutics's total assets?
Monopar Therapeutics (MNPR) reported total assets of $137.98M in Q1 2026.
How has Monopar Therapeutics's total assets changed year-over-year?
Monopar Therapeutics's total assets increased by 150.5% year-over-year, from $55.09M to $137.98M.
What is the long-term trend for Monopar Therapeutics's total assets?
Over 5 years (2020 to 2025), Monopar Therapeutics's total assets has grown at a 52.8% compound annual growth rate (CAGR), from $16.87M to $140.72M.
What does total assets mean?
The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.